119 results
8-K
EX-99.1
NTBL
Notable Labs Ltd
12 Apr 24
Notable Labs Reports 2023 Financial Results and Provides a Business Update
8:44am
for the year ended December 31, 2023 was $0.2 million.
Research and development expenses for the year ended December 31, 2023 were $4.7 million, compared
8-K/A
EX-99.3
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:15pm
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income, net
Net income (loss) per share, basic … , Ltd. is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce or eliminate its research and development
8-K/A
EX-99.2
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:00pm
:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense), net
Net loss per share, basic … of expanded research and development activities until regulatory approval is granted. Regulatory approval is not guaranteed and may never be obtained
8-K/A
EX-99.3
0qxcgth3th by72
29 Nov 23
Financial Statements and Exhibits
5:00pm
8-K/A
EX-99.4
36f6jq0bb4sj1l3g0x
29 Nov 23
Financial Statements and Exhibits
5:00pm
425
EX-10.1
nwz6yb m4xp
2 Oct 23
Business combination disclosure
5:31pm
8-K
EX-10.1
lpgywrmpjqku9d2tn w1
2 Oct 23
Other Events
5:30pm
424B3
xfdq elljmd
2 Oct 23
Prospectus supplement
5:29pm
424B3
yqr43li
5 Sep 23
Prospectus supplement
6:02pm
425
EX-99.1
d0w845demkk khkbc0cn
14 Aug 23
Business combination disclosure
8:06am
8-K
EX-99.1
lps5oqrbo2tgjpnq4z
14 Aug 23
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8:05am
S-4/A
0ovza21va2vsimg y2tw
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
10-Q
97yw7luhunxb7mxd55w3
15 May 23
Quarterly report
4:30pm